Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives

• Published in: British Medical Journal Vol. 1; no. 6053; pp. 78 - 81
• Main Authors: Kanis, J A, Russell, R G
• Format: Journal Article
• Language: English
• Published: England British Medical Journal Publishing Group 08.01.1977; BMJ Publishing Group LTD
• Subjects: Calcium - urine; Dihydrotachysterol - adverse effects; Dihydroxycholecalciferols - adverse effects; Humans; Hydroxycholecalciferols - adverse effects; Hypercalcemia - chemically induced; Hypercalcemia - metabolism; Time Factors; Vitamin D - adverse effects
• ISSN: 0007-1447; 1468-5833
• DOI: 10.1136/bmj.1.6053.78

The rate of reversal of hypercalcaemia or hypercalciuria induced by calciferol, dihydrotachysterol, 1-alpha-hydroxycholecalciferol (1-alpha-OHD3), or 1-alpha, 25-dihydroxycholecalciferol (1-alpha, 25-(OH)2D3) was measured in three normal subjects, two patients with osteoporosis, and 14 patients with disorders resistant to vitamin D. The half time for reversal after stopping 1-alpha, 25 (OH)2D3 was less than that after stopping 1-alpha-OHD3, calciferol, or dihydrotachysterol. The differences observed were independent of the dose given or length of treatment. When 1-alpha-OHD3 or 1-alpha-25-(OH)2D3 was stopped patients with vitamin D resistant states (hypoparathyroidism, renal tubular hypophosphataemia, or chronic renal failure) showed less rapid reversal of hypercalcaemia and hypercalciuria than did normal subjects. These studies show one potential advantage of 1-alpha-25-(OH)2D3 over vitamin D, and possibly over 1-alpha-OHD3, in the management of vitamin D resistant states.